特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

生体機能チップの世界市場:成長率、動向および予測分析(2020年~2025年)

Organ-on-chip Market - Growth, Trends, and Forecasts (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 708602
出版日 ページ情報 英文 95 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.99円で換算しております。
生体機能チップの世界市場:成長率、動向および予測分析(2020年~2025年) Organ-on-chip Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日: 2020年06月01日 ページ情報: 英文 95 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

生体機能チップは、連続的に灌流されたチャンバーを含むマイクロ流体細胞培養装置です。このチップは、肺、腸、肝臓、心臓、および他の臓器などの臓器内の血流および気流のための狭い経路を形成します。そのような装置は、従来の2Dおよび3D培養システムを使用しては実現不可能である複数レベルの組織および器官機能性を生み出します。疾患モデリング、患者層別化、表現型スクリーニングなど、幅広い用途があります。

当レポートでは、世界の生体機能チップ市場について調査分析し、市場概要、市場力学、市場区分、地域別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査の成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 動物実験の代替案の要件
    • 薬物毒性の早期発見の必要性
    • 新製品の発売と技術の進歩
  • 市場阻害要因
    • 生体機能チップモデルの複雑性
  • 業界の魅力:ファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争の激しさ

第5章 市場区分

  • 臓器タイプ
    • 肝臓
    • 心臓
    • 他の臓器タイプ
  • アプリケーション別
    • 創薬
    • 毒物学研究
    • その他の用途
  • エンドユーザー別
    • 製薬およびバイオテクノロジー企業
    • 学術研究機関
    • 他のエンドユーザー
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • その他の国々(ROW)

第6章 競合情勢

  • 企業プロファイル
    • AxoSim Inc.
    • BiomimX SRL
    • Elveflow
    • Emulate Inc.
    • Hurel Corporation
    • InSphero AG
    • MIMETAS BV
    • Nortis Inc.
    • Tara Biosystems
    • TissUse GmbH

第7章 市場機会および将来の動向

目次
Product Code: 64233

An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional 2D and 3D culture systems. It offers a wide range of applications, such as disease modeling, patient stratification, and phenotypic screening.

The organ-on-chip market is driven by factors, such as a requirement for alternatives for animal testing, the need for early detection of drug toxicity, and new product launches and advancements in technology that are also responsible for driving the market. Furthermore, the surging initiatives by pharmaceutical companies, to invest and investigate drug repurposing utilizing organs-on-chips models, are expected to drive the growth of the organs-on-chip market.

The demand for personalized medication and the vast applications of organ-on-chip beyond the pharmaceutical industry are the major factors creating growth opportunities for market players. There are also increasing product launches by several key players, intended to expand their product portfolio, which are further expected to increase their market in the future.

Key Market Trends

Heart-related Application is Expected to Exhibit the Fastest Growth Rate over the Forecast Period

  • Organs-on-a-chip technologies have been proposed to mimic the dynamic conditions of the cardiovascular system, particularly heart and general vasculature. These systems pay particular attention to mimicking structural organization, shear stress, transmural pressure, mechanical stretching, and electrical stimulation. Heart- and vasculature-on-a-chip platforms have been successfully generated, to study a variety of physiological phenomena, model diseases, and probe the effects of drugs.
  • Moreover, cardiovascular diseases (CVD) are rising. As per the American Heart Association 2019 statistics, CVD is the leading global cause of death, accounting for more than 17.6 million deaths per year in 2016, a number that is expected to grow to more than 23.6 million by 2030. Therefore, this is expected to increase the demand for more CVD researches, which may increase the use of heart-on -a-chip devices, in turn, boosting the market growth.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

  • Currently, North America dominates the organ-on-chip market, owing to factors, such as the availability of a wide range of services offered by major players (which includes customized designing of new chips with specific organ arrangements) and an increase in toxicological testing of chemicals on the different types of organ cells. Huge investments are being made by the public and private institutes for their research. This has further increased the growth in the market studied.

Competitive Landscape

The organ-on-chip market is highly competitive and consists several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as AxoSim Inc., BiomimX SRL, Elveflow, Emulate Inc., Hurel Corporation, InSphero AG, MIMETAS BV, Nortis Inc., Tara Biosystems Inc., and TissUse GmbH, is, in turn, increasing the overall competitive rivalry in the market. Product advancements and improvements in the organ-on-chip platforms by the major players are increasing the competitive rivalry.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Requirement of Alternative for Animal Testing
    • 4.2.2 Need for Early Detection of Drug Toxicity
    • 4.2.3 New Products Launches and Advancements in Technology
  • 4.3 Market Restraints
    • 4.3.1 Complexity of Organ-on-chip Models
  • 4.4 Industry Attractiveness - Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Organ Type
    • 5.1.1 Liver
    • 5.1.2 Heart
    • 5.1.3 Lung
    • 5.1.4 Other Organ Types
  • 5.2 By Application
    • 5.2.1 Drug Discovery
    • 5.2.2 Toxicology Research
    • 5.2.3 Other Applications
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biotechnology Companies
    • 5.3.2 Academic and Research Institutes
    • 5.3.3 Other End Users
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AxoSim Inc.
    • 6.1.2 BiomimX SRL
    • 6.1.3 Elveflow
    • 6.1.4 Emulate Inc.
    • 6.1.5 Hurel Corporation
    • 6.1.6 InSphero AG
    • 6.1.7 MIMETAS BV
    • 6.1.8 Nortis Inc.
    • 6.1.9 Tara Biosystems Inc.
    • 6.1.10 TissUse GmbH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS